Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Humanin regulatory status

Current status of Humanin in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Humanin?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
Humanin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. Without a listing, a 503A pharmacy has no federal basis to compound it as a bulk substance. It is not eligible for 503B outsourcing. Products sold under this name for human use are unapproved drugs.
WADA
WADA prohibited
Access path
  1. Not legally available: no approved product and no 503A bulks listing.
  2. Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Full Humanin page: evidence, dosing in the literature, and sources

How has the status of Humanin changed over time?

No dated regulatory event has been recorded for Humanin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Humanin and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026